Chun-Hwa Chen
Overview
Explore the profile of Chun-Hwa Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li M, Coumar M, Lin S, Lin Y, Huang G, Chen C, et al.
J Med Chem
. 2023 Feb;
66(4):2566-2588.
PMID: 36749735
The development of orally bioavailable, furanopyrimidine-based double-mutant (L858R/T790M) EGFR inhibitors is described. First, selectivity for mutant EGFR was accomplished by replacing the ()-2-phenylglycinol moiety of with either an ethanol or...
2.
Lin S, Chang C, Coumar M, Chen P, Kuo F, Chen C, et al.
Bioorg Chem
. 2020 Mar;
98:103689.
PMID: 32171993
In an effort to develop new cancer therapeutics, we have reported clinical candidate BPR1K871 (1) as a potentanticancercompound in MOLM-13 and MV4-11 leukemia models, as well as in colorectal and...
3.
Lin S, Chang Hsu Y, Peng Y, Ke Y, Lin W, Sun H, et al.
J Med Chem
. 2019 Sep;
62(22):10108-10123.
PMID: 31560541
Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine , which...
4.
Chang Hsu Y, Coumar M, Wang W, Shiao H, Ke Y, Lin W, et al.
Oncotarget
. 2016 Nov;
7(52):86239-86256.
PMID: 27863392
The design and synthesis of a quinazoline-based, multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and other malignancies is reported. Based on the previously reported furanopyrimidine 3, quinazoline...
5.
Chang C, Lin W, Ke Y, Lin Y, Wang W, Chen C, et al.
Eur J Med Chem
. 2016 Aug;
124:186-199.
PMID: 27573544
Aurora kinases have emerged as important anticancer targets so that there are several inhibitors have advanced into clinical study. Herein, we identified novel indazole derivatives as potent Aurora kinases inhibitors...
6.
Wu J, Lin S, Liao F, Hsiao W, Lee L, Peng Y, et al.
J Med Chem
. 2015 Sep;
58(19):7807-19.
PMID: 26348881
A structure-based virtual screening strategy, comprising homology modeling, ligand-support binding site optimization, virtual screening, and structure clustering analysis, was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors. Compound...
7.
Ke Y, Singh V, Coumar M, Chang Hsu Y, Wang W, Song J, et al.
Sci Rep
. 2015 Jun;
5:11702.
PMID: 26118648
The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors has emerged as a target-based alternative to traditional chemotherapy for the treatment of acute myeloid leukemia (AML). In...
8.
Chen C, Hsu J, Lin W, Lu C, Yen S, Hsu T, et al.
Eur J Med Chem
. 2015 Jun;
100:151-61.
PMID: 26081023
Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML). However, clinical data have been underwhelming due to incomplete inhibition of FLT3...
9.
Hsu K, Sung T, Lin C, Chiu Y, Hsu J, Hung H, et al.
Sci Rep
. 2015 Jun;
5:10938.
PMID: 26077136
Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred...
10.
Ke Y, Coumar M, Shiao H, Wang W, Chen C, Song J, et al.
Eur J Med Chem
. 2014 Jun;
83:226-35.
PMID: 24960626
Here we report for the first time the use of fit quality (FQ), a ligand efficiency (LE) based measure for virtual screening (VS) of compound libraries. The LE based VS...